Literature DB >> 18327805

N-glycoprotein profiling of lung adenocarcinoma pleural effusions by shotgun proteomics.

Alex Soltermann1, Reto Ossola, Sandra Kilgus-Hawelski, Arnold von Eckardstein, Tobias Suter, Ruedi Aebersold, Holger Moch.   

Abstract

BACKGROUND: Malignant pleural effusion of advanced lung adenocarcinoma may be a valid source for detection of biomarkers, such as N-glycosylated proteins (N-GP), because tumor cells grow during weeks in this liquid. The authors aimed for creation of N-GP effusion profiles from routine cytology specimens to detect relevant biomarkers.
METHODS: Hundred microliters of malignant pleural effusions of 5 patients with lung adenocarcinoma and 5 nonmalignant controls were used for triplicate N-GP capture by solid-phase extraction. After trypsin digest and PNGase F release, a liquid chromatography separation connected online to a tandem mass spectrometer was performed by liquid chromatography/tandem mass spectrometry (LC/MS/MS).
RESULTS: In the total of 10 samples, 170 and 278 nonredundant proteins were detected with probabilities of >or=.9 and >or=.5, respectively. The specificity for the N-glycomotif was 88% at P >or= .9. Penetration into the moderate to low protein concentration range (microg-ng/mL) occurred, and several proteins associated with tumor progression or metastasis were identified, including CA-125, CD44, CD166, lysosome-associated membrane glycoprotein 2 (LAMP-2), multimerin 2, and periostin. MS identifications were correlated with the corresponding immunoreactivity in either effusion fluid or tumor tissue.
CONCLUSIONS: In conclusion, reduction of sample complexity by N-GP capturing allows detection of proteins in the mug to ng/mL range. Pleural effusion is a useful source for biomarker research in lung cancer. Copyright (c) American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18327805     DOI: 10.1002/cncr.23349

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

Review 1.  Mass spectrometry based glycoproteomics--from a proteomics perspective.

Authors:  Sheng Pan; Ru Chen; Ruedi Aebersold; Teresa A Brentnall
Journal:  Mol Cell Proteomics       Date:  2010-08-24       Impact factor: 5.911

Review 2.  Application of glycoproteomics for the discovery of biomarkers in lung cancer.

Authors:  Qing Kay Li; Edward Gabrielson; Hui Zhang
Journal:  Proteomics Clin Appl       Date:  2012-06       Impact factor: 3.494

Review 3.  Comparative glycoproteomics: approaches and applications.

Authors:  Xin Wei; Lingjun Li
Journal:  Brief Funct Genomic Proteomic       Date:  2008-12-17

Review 4.  Update on biomarkers for the detection of lung cancer.

Authors:  Eloisa Jantus-Lewintre; Marta Usó; Elena Sanmartín; Carlos Camps
Journal:  Lung Cancer (Auckl)       Date:  2012-06-11

5.  Relevance of periostin splice variants in renal cell carcinoma.

Authors:  Laura Morra; Markus Rechsteiner; Silvia Casagrande; Van Duc Luu; Roger Santimaria; Pierre A Diener; Tullio Sulser; Glen Kristiansen; Peter Schraml; Holger Moch; Alex Soltermann
Journal:  Am J Pathol       Date:  2011-07-18       Impact factor: 4.307

6.  Integrated mass spectrometry-based analysis of plasma glycoproteins and their glycan modifications.

Authors:  Hong Wang; Chee-Hong Wong; Alice Chin; Ayumu Taguchi; Allen Taylor; Samir Hanash; Sadanori Sekiya; Hidenori Takahashi; Masaki Murase; Shigeki Kajihara; Shinichi Iwamoto; Koichi Tanaka
Journal:  Nat Protoc       Date:  2011-02-10       Impact factor: 13.491

7.  In-depth proteomic analysis of nonsmall cell lung cancer to discover molecular targets and candidate biomarkers.

Authors:  Takefumi Kikuchi; Mohamed Hassanein; Joseph M Amann; Qinfeng Liu; Robbert J C Slebos; S M Jamshedur Rahman; Jacob M Kaufman; Xueqiong Zhang; Megan D Hoeksema; Bradford K Harris; Ming Li; Yu Shyr; Adriana L Gonzalez; Lisa J Zimmerman; Daniel C Liebler; Pierre P Massion; David P Carbone
Journal:  Mol Cell Proteomics       Date:  2012-07-03       Impact factor: 5.911

8.  Periostin is up-regulated in high grade and high stage prostate cancer.

Authors:  Verena Tischler; Florian R Fritzsche; Peter J Wild; Carsten Stephan; Hans-Helge Seifert; Marc-Oliver Riener; Thomas Hermanns; Ashkan Mortezavi; Josefine Gerhardt; Peter Schraml; Klaus Jung; Holger Moch; Alex Soltermann; Glen Kristiansen
Journal:  BMC Cancer       Date:  2010-06-09       Impact factor: 4.430

Review 9.  Targeted proteomic strategy for clinical biomarker discovery.

Authors:  Ralph Schiess; Bernd Wollscheid; Ruedi Aebersold
Journal:  Mol Oncol       Date:  2008-12-11       Impact factor: 6.603

Review 10.  Glycoproteomics using fluid-based specimens in the discovery of lung cancer protein biomarkers: promise and challenge.

Authors:  Qing Kay Li; Ed Gabrielson; Frederic Askin; Daniel W Chan; Hui Zhang
Journal:  Proteomics Clin Appl       Date:  2013-01       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.